Does the rs6511720 GG genotype lack the LDL-lowering protective signal seen with the T allele?

The rs6511720 single nucleotide polymorphism, located within intron 1 of the low-density lipoprotein receptor (LDLR) gene, is a critical genetic determinant of lipid regulation and cardiovascular health.

Clinical evidence

• Cardiovascular Risk Reduction: Large-scale genetic analyses, including data from the CARDIoGRAM and C4D consortia, demonstrate that carrying the minor T allele of rs6511720 is associated with a robust ~12% reduction in the odds of coronary heart disease.
• Vascular Protection: The protective lipid-lowering effects of the T allele extend beyond coronary disease, showing a significant association with a reduced risk of abdominal aortic aneurysms.
• Genotypic Risk Profile: Individuals homozygous for the common G allele (the GG genotype) do not possess this protective signal. Lacking the minor T allele, those with the GG genotype exhibit typical, relatively higher baseline circulating LDL cholesterol (LDL-C) and standard cardiovascular risk.

Mechanistic explanations

• Enhancer Activity: Functional research reveals that the rs6511720 T allele acts as a strong genetic enhancer that directly increases LDLR promoter activity.
• Hepatic Expression and LDL Clearance: This enhancer activity upregulates hepatic LDLR expression. The resulting increase in receptor density on liver cells enhances the clearance of circulating LDL particles from the bloodstream, driving down plasma LDL-C and total cholesterol.

Bottom line

• The LDLR-locus rs6511720 T allele is highly protective, reducing coronary heart disease risk and LDL-C through enhanced receptor expression and hepatic clearance. Conversely, individuals with the rs6511720 GG genotype lack this genetically determined protection, predisposed instead to relatively higher baseline LDL-C levels.